Immunovia AB (STO:IMMNOV), a diagnostic company developing and commercialising highly accurate blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform called IMMray, on Wednesday provided an update on the actions that the company is taking to support patients, employees, and public health initiatives in response to the COVID-19 pandemic.

The company stared that despite these extraordinary times, it remains focused on the Q3 2020 sales start for the first test for early diagnosis of pancreatic cancer, IMMray PanCan-d.

According to Immunovia, it will continue to monitor the global development of the COVID-19 epidemic closely and enact strategies that adhere to authorities' guidelines in each of the countries where it is active in order to protect the health of its employees and the greater community to slow down and minimise the spread of the virus. In line with these critical efforts, Immunovia is taking proactive steps to protect and limit the exposure of its personnel.

In addition, inventories of critical consumables have been secured to enable the uninterrupted continuation of its commercialisation start.